Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of DX126-262 in HER2-overexpressing advanced or metastatic urothelial carcinoma
CTR20221490Phase 2Active
- Sponsor
- Hangzhou DAC Biotech
- Start
- Aug 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DX126-262 in transitional cell carcinoma (TCC) (2 arms), sponsored by Hangzhou DAC Biotech. Primary endpoint: Objective response rate. Started Aug 2022; status: active.
02
Drugs
DX126-262
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20221490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221490.